Imagine a world where cancer is not just treated, but reprogrammed out of existence by a patient’s own immune system.
Join us for a live webinar that takes you to the forefront of this transformative field. In collaboration with the International Conference on Lymphocyte Engineering (ICLE), this session will explore how genome editing is revolutionizing T cell–based cancer immunotherapy, from CAR and TCR engineering to the latest safety innovations and emerging strategies.
Through expert insights and interactive discussions, you will gain a clear understanding of the milestones that have shaped the field, the challenges researchers are tackling today, and the innovations poised to redefine cancer treatment tomorrow.
Live Event Highlights
- Topic: Approved and Emerging Lymphocyte Engineering Technologies
- Date & Time: Tuesday, 17 February 2026 | 4:00 PM CET, 10:00 AM EST
Key Topics
- Overview of approved and emerging T cell engineering technologies
- CAR and TCR therapies: design, safety, and clinical impact
- Innovations in genome editing for adoptive T cell therapy
- Challenges and future directions in engineered lymphocyte therapies
Speakers
Dr. Chiara Bonini
Dr. Bonini leads the Experimental Hematology Unit at IRCCS San Raffaele Scientific Institute. Her research focuses on allogeneic stem cell transplantation and the development and clinical validation of cell and gene therapies for cancer. She has authored over 190 peer-reviewed publications, holds multiple international patents, and has received prestigious awards, including the Outstanding Achievement Award from ESGCT (2024) and the DKMS Mechtild Harf Science Award (2025).
Moderator
Prof. Adi Barzel
Scientist, inventor, and entrepreneur specializing in gene therapy, immunotherapy, and genome editing. He has co-founded several biotech companies, including LogicBio Therapeutics and Tabby Therapeutics, and has been instrumental in developing transformative treatments from bench to bedside. Prof. Barzel serves as president of the Israeli Society of Gene and Cell Therapy and chairs the International Conference on Lymphocyte Engineering.